MethylGene Reports Positive Interim Results From Two Clinical Programs At American Society of Clinical Oncology Conference

Interim Data From HDAC Inhibitor, MGCD0103, Includes Three Leukemia Patients Exhibiting Complete Bone Marrow Responses

MORE ON THIS TOPIC